Skip to content Skip to footer
Subscribe Now
Regeneron & Sanofi
NEWS

Regeneron and Sanofi Expand Immunology Alliance in a Deal Valued at ~$8B

Shots: The companies expanded their alliance to add 4 long-acting, Regeneron-invented antibodies targeting IL-13 (REGN20423), IL-4×IL-13 bispecific, IL-4 & IL-4Rα. REGN20423 is in P-I for atopic dermatitis, while the other 3 are expected to enter clinical studies in 2027 As per the expanded agreement, Regeneron & Sanofi will co-develop & co-commercialize the assets, with Regeneron…
2 days ago

Read more

NEWS

Tolerance Bio and Tanabe Pharma Partner for MT-2990 in Deal With Up to $560M in Milestones

Shots: Tolerance Bio has entered into an exclusive license agreement with Tanabe Pharma for MT-2990, an anti-IL-33 monoclonal antibody, across all indications Tanabe Pharma has granted Tolerance Bio worldwide development & manufacturing rights, and ex-Japan exclusive commercialization rights for MT-2990 (TLB-33), while Tanabe will retain commercialization rights in Japan As per the deal, Tanabe will…
3 days ago

Read more

NEWS

Atavistik Bio Inks ~$1.97B Partnership with Roche to Advance Allosteric Small Molecules for CVRM Diseases

Shots: Atavistik Bio has entered into a strategic research collaboration with Roche to discover & develop novel small molecules against multiple targets for cardiovascular, renal, and metabolic (CVRM) diseases, using Atavistik’s AMPS platform As per the deal, Atavistik Bio will be responsible for discovery & research activities for the collaboration targets, with Roche responsible for…
September 25, 2026

Read more

NEWS

Amberstone and Henlius Partner to Develop Conditionally Activated T-Cell Engagers for Solid Tumors

Shots: Amberstone Biosciences has entered into a collaboration & license agreement with Henlius Biotech to advance conditionally activated T-cell engagers for the treatment of solid tumors As per the deal, Amberstone will use its T-MATE platform to generate preclinical candidates against ~2 Henlius-selected targets, while Henlius will lead subsequent research, development, manufacturing & global commercialization…
September 25, 2026

Read more

NEWS

Earendil Labs Inks $1.5B+ Research Collaboration with Genentech to Advance Bispecific Antibodies in Oncology

Shots: Earendil Labs has entered into a research collaboration with Genentech to discover and develop multiple therapeutic bispecific antibody programs in oncology Earendil Labs will lead antibody discovery & research through early clinical development for programs targeting certain pre-agreed target combinations, while Genentech will take over global clinical development & commercialization As per the deal,…
September 24, 2026

Read more

NEWS

Variant Bio Broadens Discovery Collaboration with Boehringer Ingelheim to Cardiovascular Disease Targets

Shots: Variant Bio has expanded its multi-year research collaboration & license agreement with BI to discover and validate novel cardiovascular disease targets using its Inference platform, building on their existing kidney disease collaboration As per the terms of the expanded agreement, Variant Bio will receive an additional upfront payment & over $250M in potential license…
September 24, 2026

Read more

NEWS

Envisagenics and Boehringer Ingelheim Sign >$1B Cancer Drug Development Deal

Shots: Envisagenics has entered a multi-year research collaboration & option agreement with BI to validate tumor-specific targets for developing first-in-class precision therapies for solid tumors, using Envisagenics’ AI-powered SpliceCore platform  Collaboration builds on targets identified through SpliceCore to validate their potential across ADCs, TCEs & multispecific Abs, with BI having an option to exclusively license…
September 23, 2026

Read more

NEWS

Grünenthal to Acquire Bayer’s Stivarga for ~€375M

Shots: Grünenthal has entered into an agreement with Bayer to acquire Stivarga for ~€375M (~$430.67M), subject to customary closing conditions incl. regulatory approval, with the transaction expected to close by the end of 2026 or early 2027 Stivarga (regorafenib) is an oral multikinase inhibitor indicated for metastatic colorectal cancer, hepatocellular carcinoma, & gastrointestinal stromal tumours…
September 21, 2026

Read more

NEWS

Orbis Medicines and Novo Partner on Oral Macrocycle Drugs in a ~$1.4B Deal

Shots: Orbis Medicines has entered into a strategic collaboration & license agreement with Novo to discover & develop next-generation oral macrocycle therapeutics for cardiometabolic diseases  As per the deal, Orbis will receive ~$1.4B in upfront, and development & commercial milestone payments, plus tiered royalties on future product sales, while Novo will also make a strategic…
September 17, 2026

Read more

Load more